Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MCP-1 in psoriatic patients: effect of biological therapy.

The Journal of dermatological treatment - 1 Feb 2014

Lembo Serena, Capasso Rosanna, Balato Anna, Cirillo Teresa, Flora Filomena, Zappia Vincenzo, Balato Nicola, Ingrosso Diego, Ayala Fabio

Abstract excerpt

BACKGROUND: Monocyte chemoattractant protein-1 (MCP-1) is a chemokine locally and systemically augmented in psoriasis. A single nucleotide polymorphism in MCP-1 promoter region -2518A→G is associated with higher gene expression. OBJECTIVE: The aim was to evaluate MCP-1 plasma level in psoriatic patients and to relate any association in plasmatic and cutaneous MCP-1 with clinical improvement due to biological...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adalimumab
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemokine CCL2

Share to Etanercept

Share to Immunologic Factors

Share to Psoriasis

Share to Receptors, Tumor Necrosis Factor

Share to Remission Induction

Source

Identifiers

PMID: 23480385
DOI: 10.3109/09546634.2013.782091

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

MCP-1 in psoriatic patients: effect of biological therapy.PMID 23480385Read ↗

A functional promoter polymorphism in monocyte chemoattractant protein‐1 is associated with psoriasisSemantic proximity Read ↗

The TNFRSF1B rs1061622 polymorphism (p.M196R) is associated with biological drug outcome in Psoriasis patients.Semantic proximity Read ↗

The MCP-1 rs1024611 and MTHFR rs1801133 gene variations and expressions in alopecia areata: A pilot study.Semantic proximity Read ↗

TNF-alpha gene polymorphisms can help to predict response to etanercept in psoriatic patients.Semantic proximity Read ↗

Biomolecular index of therapeutic efficacy in psoriasis treated with anti-TNF-α agents.Semantic proximity Read ↗

The Role of Tumor Necrosis Factor-α Blockers in Psoriatic Disease. Therapeutic Options in Psoriatic Arthritis.Semantic proximity Read ↗

Polymorphism of monocyte chemoattractant protein 1 in Crohn's disease.Semantic proximity Read ↗

Analysis of the monocyte chemoattractant protein 1 -2518 promoter polymorphism in Korean patients with alopecia areata.Semantic proximity Read ↗

Study of lncRNAs expression profile in the response to biological drugs in Psoriatic Arthritis: MEG3 could be a potential genomic biomarker of therapy efficacy.Semantic proximity Read ↗

High serum levels of HIF-1α in psoriatic patients correlate with an over-expression of IL-6Semantic proximity Read ↗

AntiTNF-alpha Therapy Normalizes Levels of Lipids and Adipokines in Psoriatic Patients in the Real-life SettingsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.